Apatinib Plus Irinotecan as Second-line Treatment in AGC or EGJA
Status:
Unknown status
Trial end date:
2020-09-01
Target enrollment:
Participant gender:
Summary
This is a prospective, multicenter, single-group clinical study of Apatinib Plus Irinotecan
as second-line treatment in locally advanced or metastatic gastric or gastroesophageal
junctional adenocarcinoma.
Phase:
Phase 2
Details
Lead Sponsor:
China Medical University, China
Collaborators:
Anshan Tumor Hospital Benxi Cental Hospital Benxi central hospital General Hospital of Shenyang Military Region Jilin University Sino-Japanese Friendship Hospital Liaoning Tumor Hospital & Institute Liaoyang Central Hospital Liaoyang Petrochemical General Hospital Panjin Central Hospital Shengjing Hospital The Affiliated Tumor Hospital of Harbin Medical University The First Affiliated Hospital of Dalian Medical University The First Hospital of Jilin University The People's Hospital of Liaoning Province The Second Affiliated Hospital of Dalian Medical University The Second Affiliated Hospital of Harbin Medical University